ArticleBMC infectious diseases2025
Convergence of multidrug resistance and efflux-mediated biocide tolerance in klebsiella pneumoniae ST307: implications for nosocomial infection control in Iranian hospitals.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Surface Contamination by Multidrug-Resistant Gram-Negative Bacteria in a Healthcare Facility: Resistance Determinants and Biofilm-Associated Adhesion.International journal of microbiology · 2026Article
- Epidemiological and characteristic differences of hypervirulent and classicalFrontiers in cellular and infection microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe relentless evolution of K. pneumoniae ST307 into a "superbug" with dual resistance to last-line antibiotics and hospital disinfectants poses an existential threat to infection control. This study characterizes the molecular epidemiology, resistance profiles, and biocide tolerance of ST307 isolates from Iranian hospitals, highlighting its role in nosocomial outbreaks.
methodsA multicenter cross-sectional analysis of 500 K. pneumoniae isolates (2022-2024) utilized CLSI-compliant disk diffusion, broth microdilution, and PCR for resistance genes (bla
resultsST307 accounted for 30% (150/500) of isolates, predominantly from ICUs. Resistance rates included meropenem (60.0%; MIC₅₀ >32 µg/mL), ciprofloxacin (75.3%), and gentamicin (45.3%). Colistin retained efficacy (85.3% susceptibility). Elevated biocide MICs (chlorhexidine ≥ 0.5% [70.0%]; benzalkonium chloride ≥ 0.1% [65.3%]) correlated with cepA (65.3%) and qacED1 (70.0%) positivity (p < 0.01). Carbapenemase genes bla
conclusionsST307's convergence of resistance mechanisms represents a catastrophic failure of current infection control frameworks. Without immediate interventions-such as ICU closures for deep disinfection, restricted colistin/tigecycline use, and genomic surveillance mandates-this clone will dominate Iranian hospitals within 3-5 years.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.